Studies diaphragm movement after valve treatment for emphysema in COPD patients
Observes diaphragm movement before and after endobronchial valve treatment in adults with COPD.
Plain-language title generated from the registry record
Registry title: The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility
Key facts
- Where
- Aarhus, DenmarkSee the site
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aarhus University Hospital
- Trial code
- NCT06163131
- Record updated
- 8 December 2023
- Original description
In some patients with chronic obstructive pulmonary disease (COPD) the breathlessness is caused by hyperinflation of the lungs. This causes difficulty breathing air out and makes it harder to breath in new air and limits the movement of the diaphram. The diaphragm is the muscle used for breathing between the chest and the stomach. Some of these patients can receive treatment with endobronchial valves, where one-ways are inserted into the bronchial system the let out some of the excess air, and thereby relieve breathlessness.Read full original descriptionShow less
The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility
In some patients with chronic obstructive pulmonary disease (COPD) the breathlessness is caused by hyperinflation of the lungs. This causes difficulty breathing air out and makes it harder to breath in new air and limits the movement of the diaphram. The diaphragm is the muscle used for breathing between the chest and the stomach. Some of these patients can receive treatment with endobronchial valves, where one-ways are inserted into the bronchial system the let out some of the excess air, and thereby relieve breathlessness.
The goal of this observational study is to investigate the effect of endobronchial valves on the mobility of the diaphragm in patients with chronic obstructive pulmonary disease. The main questions it aims to answer are:
* If the movement of the diaphragm improves after treatment with endobronchial valves. * If there is a link between improvement of diaphragm function and improvement of symptoms, lung function and physical ability. * If ultrasound scan immediately after the treatment will predict which patients will benefit from the treatment.
Participants will undergo ultrasound before, 1 day after and 90 days after the procedure, and lung function examinations from their already planned control visits will be collected.
Inclusion: Patients selected to receive treatment with endobronchial valves; Signed informed consent.
Exclusion: Neuromuscular disease interfering with diaphragm function; Pleural effusion at time of preoperative or 90-days postoperative ultrasound.